On 2015 Jan 07, Jim Woodgett commented:

The authors refer to a prior publication (PMID: 20939016) that correctly describes AR28 as a GSK-3alpha/beta inhibitor rather than a GSK-3beta inhibitor as described in the title and throughout most of the manuscript. Given the authors do not address specificity of AR28 in this publication, the Introductory comments seem unsupported: "While LiCl and BIO circumvent this problem by acting on GSK3β, downstream of the ligand/receptor binding, they are not ideal, with off target effects and toxicity (Davies et al., 2000, Meijer et al., 2003 and Liu et al., 2011)." It is also unusual in describing a novel inhibitor to not provide any details of the molecule. This inhibitor is also known as AZD2858 (PMID: 22142634), was developed by Astra Zeneca and is available from several commercial sources (e.g. Selleck Chemicals, Cayman Chemicals).

On 2015 Jan 07, Jim Woodgett commented:

The authors refer to a prior publication (PMID: 20939016) that correctly describes AR28 as a GSK-3alpha/beta inhibitor rather than a GSK-3beta inhibitor as described in the title and throughout most of the manuscript. Given the authors do not address specificity of AR28 in this publication, the Introductory comments seem unsupported: "While LiCl and BIO circumvent this problem by acting on GSK3β, downstream of the ligand/receptor binding, they are not ideal, with off target effects and toxicity (Davies et al., 2000, Meijer et al., 2003 and Liu et al., 2011)." It is also unusual in describing a novel inhibitor to not provide any details of the molecule. This inhibitor is also known as AZD2858 (PMID: 22142634), was developed by Astra Zeneca and is available from several commercial sources (e.g. Selleck Chemicals, Cayman Chemicals).